A study evaluated the effectiveness of vaccines against long COVID in children aged 5 to 17 years. Using data from 17 health systems, researchers found that vaccination reduced the risk of long COVID, with vaccine effectiveness (VE) being 35.4% against probable long COVID and 41.7% against diagnosed long COVID within 12 months. VE was higher in adolescents (50.3%) than in younger children (23.8%). The effectiveness decreased over time, with VE at 6 months being 61.4% and at 18 months being 10.6%. The study suggests that vaccination provides moderate protection against long COVID, with stronger effects in adolescents, who are at higher risk. The findings indicate that vaccine effectiveness against long COVID is closely tied to its effectiveness against the preceding COVID-19 infection. The study highlights the need for further research to understand the mechanisms of vaccine effectiveness against long COVID, including the role of immune response and the impact of new viral variants. The study also notes that long COVID is heterogeneous and underdiagnosed, with symptoms such as fatigue, brain fog, and respiratory issues affecting children. While vaccines reduce the risk of severe disease and short-term complications, their effectiveness against long COVID is less clear, especially in children. The study used electronic health records and found that vaccination is associated with reduced risk of long COVID for at least 12 months. The results suggest that vaccination may confer some benefit against future long-term effects of COVID-19, particularly in adolescents. The study also found that the protective effect of vaccination may be primarily through reducing the occurrence or severity of the initial infection. The study underscores the importance of continued research to understand the long-term effects of vaccination and to guide public health policy.A study evaluated the effectiveness of vaccines against long COVID in children aged 5 to 17 years. Using data from 17 health systems, researchers found that vaccination reduced the risk of long COVID, with vaccine effectiveness (VE) being 35.4% against probable long COVID and 41.7% against diagnosed long COVID within 12 months. VE was higher in adolescents (50.3%) than in younger children (23.8%). The effectiveness decreased over time, with VE at 6 months being 61.4% and at 18 months being 10.6%. The study suggests that vaccination provides moderate protection against long COVID, with stronger effects in adolescents, who are at higher risk. The findings indicate that vaccine effectiveness against long COVID is closely tied to its effectiveness against the preceding COVID-19 infection. The study highlights the need for further research to understand the mechanisms of vaccine effectiveness against long COVID, including the role of immune response and the impact of new viral variants. The study also notes that long COVID is heterogeneous and underdiagnosed, with symptoms such as fatigue, brain fog, and respiratory issues affecting children. While vaccines reduce the risk of severe disease and short-term complications, their effectiveness against long COVID is less clear, especially in children. The study used electronic health records and found that vaccination is associated with reduced risk of long COVID for at least 12 months. The results suggest that vaccination may confer some benefit against future long-term effects of COVID-19, particularly in adolescents. The study also found that the protective effect of vaccination may be primarily through reducing the occurrence or severity of the initial infection. The study underscores the importance of continued research to understand the long-term effects of vaccination and to guide public health policy.